Published on: 17 July 2023
This guidance provides evidence-based recommendations and good practice points for health professionals on the use of progestogen-only injectables (depot medroxyprogesterone acetate (DMPA), Depo-Provera) currently available in the UK. It is intended for any health care professional or health service providing contraception or conception advice in the UK.
Please read this guidance document in conjunction with any relevant clinical statements for this topic:
FSRH Response to new study on use of CHC and POC and breast cancer risk (March 2023)
FSRH CEU Statement: Contraception and Weight Gain (August 2019)
Your download should start automatically. If not download directly.